Table 1.
Pathologic Characteristics
| Case | Pathologic Diagnoses | Sclerosis and Lesionsa | Tubular Microcysts | ATI | Int inflam | IFTA | AS | FPE | TRIs on EM |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1) COVID-19–associated CG; 2) ATI | 3 gloms: 0% globally sclerotic, 67% segmentally sclerotic (2 w/ collapsing lesions) | Yes | Diffuse | Diffuseb | 10% | None | 100% | Yes |
| 2 | 1) COVID-19–associated CG; 2) IgAN; 3) ATI | 4 gloms: 0% globally sclerotic, 100% segmentally sclerotic (4 w/ collapsing lesions) | Yes | Diffuse | Diffuse | 10% | None | >95% | No |
| 3 | 1) COVID-19–associated CG; 2) DGS (class III); 3) ATI | 24 gloms: 50% globally sclerotic, 25% segmentally sclerotic (3 w/ collapsing lesions, 3 w/ noncollapsing FSGS lesions) | No | Diffuse | Diffuseb | 70% | Mod | >95% | No |
| 4 | 1) COVID-19–associated CG; 2) ATI | 11 gloms: 27% globally sclerotic, 18% segmentally sclerotic (2 w/ collapsing lesions) | Yes | Diffuse | Diffuse | 20% | Mod | 90% | No |
| 5 | 1) COVID-19–associated CG; 2) ATI | 18 gloms: 22% globally sclerotic, 22% segmentally sclerotic (4 w/ collapsing lesions) | Yes | Diffuse | Focalb | 20% | Mild | 60%-70% | Yes |
| 6 | 1) COVID-19–associated CG; 2) ATI | 7 gloms: 0% globally sclerotic, 29% segmentally sclerotic (2 w/ collapsing lesions) | Yes | Diffuse | Focal | 10% | Mild | 100% | Yes |
| 7 | 1) COVID-19–associated CG; 2) ATI | 42 gloms: 12% globally sclerotic, 31% segmentally sclerotic (9 w/ collapsing lesions, 4 w/ noncollapsing FSGS lesions) | No | Diffuse | Diffuse | 20% | Mild | 20% | No |
| 8 | 1) COVID-19–associated CG; 2) MN (PLA2R-negative, stage II-III); 3) ATI | 48 gloms: 17% globally sclerotic, 8% segmentally sclerotic (2 w/ collapsing lesions, 2 w/ noncollapsing FSGS lesions) | Yes | Diffuse | Diffuse | 40% | Severe | 50% | No |
| 9 | 1) MN (PLA2R-negative, stage I-II); 2) mesangial sclerosing glomerulopathy; 3) ATI | 19 gloms: 42% globally sclerotic, 5% segmentally sclerotic (1 w/ noncollapsing FSGS lesions) | Yes | Diffuse | None | 10% | Mod | 100% | Yes |
| 10 | 1) Diffuse crescentic HSP nephritis; 2) ATI | 31 gloms: 3% globally sclerotic, 0% segmentally sclerotic | No | Diffuse | Focal | 0% | None | 70% | No |
| 11 | 1) DGS (class III); 2) ATI | 20 gloms: 15% globally sclerotic, 0% segmentally sclerotic | No | Diffuse | Focal | 10% | Mod | 20% | No |
| 12 | 1) DGS (class IV); 2) ATI | 20 gloms: 60% globally sclerotic, 0% segmentally sclerotic | No | Focal | Diffuse | 80% | Marked | 90% | No |
| 13 | 1) DGS (class IV); 2) ATI | 8 gloms: 75% globally sclerotic, 0% segmentally sclerotic | No | Focal | Diffuse | 70% | Mod | No viable glomeruli | EM not done |
Abbreviations: AS, arteriosclerosis; ATI, acute tubular injury; CG, collapsing glomerulopathy; DGS, diabetic glomerulosclerosis; EM, electron microscopy; FPE, percent of total peripheral capillary surface area with podocyte foot-process effacement; FSGS, focal segmental glomerulosclerosis; gloms, glomeruli; HSP, Henoch-Schönlein purpura; IFTA, percent of cortex with interstitial fibrosis and tubular atrophy; IgAN, immunoglobulin A nephropathy; int inflam, interstitial inflammation; mod, moderate; MN, membranous nephropathy; PLA2R, phospholipase A2 receptor 1; TRI, endothelial tubuloreticular inclusions.
a
Lesions only mentioned if found in any glomerulus.
b
Plasma cell rich.